<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878458</url>
  </required_header>
  <id_info>
    <org_study_id>2021KYPJ090</org_study_id>
    <nct_id>NCT04878458</nct_id>
  </id_info>
  <brief_title>Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma</brief_title>
  <acronym>PVP</acronym>
  <official_title>Effectiveness and Safety of Phacotrabeculectomy and Phacogoniotomy in Advanced Primary Angle-closure Glaucoma: a Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Shijiazhuang City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Union hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Handan City Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, parallel, open, non-inferior randomized controlled trial was conducted to&#xD;
      compare the effectiveness and safety of phacotrabeculectomy and phacogoniotomy in the&#xD;
      treatment of advanced primary angle closure glaucoma, so as to provide a better surgical&#xD;
      alternative.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is the leading cause of irreversible blindness worldwide, and primary angle closure&#xD;
      glaucoma (PACG) accounted for the majority particularly in Asia and China. The preferred&#xD;
      treatment method is anti-glaucoma surgery-trabeculectomy (Trab) combined with lens&#xD;
      extraction. Phacotrabeculectomy has become the first-line choice of anti-glaucoma suregery in&#xD;
      the treatment of advanced PACG. However, it was not an ideal method due to the bleb-related&#xD;
      complications and troublesome postoperative nursing, as well as the difficulty for surgeons,&#xD;
      caused by trabeculectomy. However, recent studies revealed that the phacoemulsification with&#xD;
      intraocular lens implantation (PEI) combined with goniosynechialysis (GSL) has achieved&#xD;
      efficacy in the treatment of PACG.&#xD;
&#xD;
      With the advent of minimally invasive glaucoma surgeries (MIGS), there is an increasing&#xD;
      number studies indicating the MIGS performed great efficacy in the treatment of primary open&#xD;
      angle glaucoma. While,there were a few small-sampled retrospective studies which showed&#xD;
      therapeutic effects in PACG. The GSL plus goniotomy (GT) could achieve great efficacy in&#xD;
      lowering the intraocular pressure of PACG patients. However, there is still a lack of high&#xD;
      quality and high-level randomized controlled trials.&#xD;
&#xD;
      Therefore, this study intends to conduct a multicenter, parallel, open, non-inferior&#xD;
      randomized controlled trial to compare the effectiveness and safety of PEI+ Trab and&#xD;
      PEI+GSL+GT in the treatment of advanced PACG, so as to provide a better surgical treatment&#xD;
      for PACG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>multicenter, parallel, open, non-inferior randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of intraocular pressure</measure>
    <time_frame>Postoperative 12, 24, 36 months.</time_frame>
    <description>Change from baseline IOP after surgery using Goldmann or non-contact tonometer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative success rate of surgery</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>(i) Complete success is defined as the postoperative IOP between 5 and 18 mmHg, and 20% reduction from baseline with no need for IOP-lowering medication.&#xD;
(ii) Qualified success is defined as the postoperative IOP between 5 and 18 mmHg, and 20% reduction from baseline with or without IOP-lowering medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative and postoperative complications</measure>
    <time_frame>0, 1, 7 day. 1, 3, 6, 12, 18, 24, 30, 36 months</time_frame>
    <description>For example, shallow anterior chamber, hyphema, persistent hypotony, corneal endothelium decompensation, endophthalmitis, and other filtering bleb-related complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-glaucomatous medications</measure>
    <time_frame>0, 1, 7 day. 1, 3, 6, 12, 18, 24, 30, 36 months</time_frame>
    <description>Numbers and types of anti-glaucomatous medications</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Visual acuity</measure>
    <time_frame>0, 1, 7 day. 1, 3, 6, 12, 18, 24, 30, 36 months</time_frame>
    <description>Uncorrected and best corrected visual acuity will be documented using ETDRS chart.</description>
  </other_outcome>
  <other_outcome>
    <measure>Degree of peripheral anterior synechia</measure>
    <time_frame>3, 12, 24, 36 months</time_frame>
    <description>The peripheral anterior synechia is checked using gonioscopy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Corneal endothelial cell counting</measure>
    <time_frame>0, 12, 24, 36 months</time_frame>
    <description>Corneal endothelial cell counting will be documented using specular microscope.</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual field</measure>
    <time_frame>0, 12, 24, 36 months</time_frame>
    <description>Visual field examination is performed using Humphrey analyzer.</description>
  </other_outcome>
  <other_outcome>
    <measure>Optic nerve head morphology and retinal parameters</measure>
    <time_frame>0, 12, 24, 36 months</time_frame>
    <description>Optic nerve head morphology and retinal parameters based on optical coherence tomography (Cirrus 5000, Zeiss, CA, USA or Spectralis, Heidelberg, Germany)</description>
  </other_outcome>
  <other_outcome>
    <measure>Measurement of quality of life</measure>
    <time_frame>0, 12, 24, 36 months</time_frame>
    <description>Quality of life is measured with EQ-5D-5L questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Filtering bleb classification</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>Filtering bleb classification based on Indiana Bleb Appearance Grading Scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Time-consuming of operation and the surgery cost</measure>
    <time_frame>1 day</time_frame>
    <description>Time-consuming of operation and the surgery cost are based on the electronic healthy system.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Glaucoma, Angle-Closure</condition>
  <arm_group>
    <arm_group_label>PEI+GSL+GT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEI+Trab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with trabeculectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy</intervention_name>
    <description>The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.</description>
    <arm_group_label>PEI+GSL+GT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>phacoemulsification with intraocular lens implantation combined with trabeculectomy</intervention_name>
    <description>The patients enrolled underwent phacoemulsification with intraocular lens implantation combined with trabeculectomy.</description>
    <arm_group_label>PEI+Trab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 40-80&#xD;
&#xD;
          2. Diagnosed with advanced PACG: meet with (1) (2) (3) or (1) (2) (4) (1) more than&#xD;
             180-degree synechial closure of anterior chamber angle on gonioscopy; (2) IOP&gt; 21mmHg&#xD;
             with or without anti-glaucoma medication; (3) Significant glaucomatous optic&#xD;
             neuropathy [cup-to-disc (C/D)ratio≥0.7, or C/D asymmetry &gt; 0.2, or the rim width at&#xD;
             superior and inferior temporal &lt; 0.1 vertical diameters of optic disc); (4) With&#xD;
             glaucoma visual field defects, such as nasal step, arcurat defect, and paracentral&#xD;
             scotoma (on reliable Humphrey analyzer using SITA-Standard 24-2 or 30-2 algorithm);&#xD;
             mead deviation ≤-12dB).&#xD;
&#xD;
          3. Patients with clinically significant cataracts with a visual acuity of less than 0.63&#xD;
             (ETDRS LogMAR), or need lens extraction assessed by an ophthalmologist;&#xD;
&#xD;
          4. Patients voluntarily participated in the study with signed informed consent and agreed&#xD;
             to follow up according to the study plan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of intraocular surgery or ocular trauma (other than laser iridotomy or laser&#xD;
             iriplasty);&#xD;
&#xD;
          2. Concomitant with other types of glaucoma, including: primary open-angle glaucoma,&#xD;
             various types of secondary glaucoma (secondary angle-closure glaucoma, steroidal&#xD;
             glaucoma, secondary angle regression glaucoma, neovascular glaucoma, inflammatory&#xD;
             secondary glaucoma, true microophthalmia, pseudoextirpation syndrome, etc.);&#xD;
&#xD;
          3. The International Standardized Ratio (INR) &gt; 3.0 for patients receiving warfarin or&#xD;
             anticoagulant therapy before surgery;&#xD;
&#xD;
          4. People with fundus disease that affects the collection of eye parameters or interferes&#xD;
             with visual field examination;&#xD;
&#xD;
          5. Long-term local or systemic use of glucocorticoids;&#xD;
&#xD;
          6. Cyclops (corrected visual acuity less than 0.01 in non-study eyes);&#xD;
&#xD;
          7. Complicated with serious systemic diseases;&#xD;
&#xD;
          8. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiulan Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiulan Zhang, MD, PhD</last_name>
    <phone>+86 13570166308</phone>
    <email>zhangxl2@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yunhe Song, MD</last_name>
    <phone>+86 13059106657</phone>
    <email>syh_oph@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiulan Zhang, MD, PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiulan Zhang, MD, PHD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Husain R, Do T, Lai J, Kitnarong N, Nongpiur ME, Perera SA, Ho CL, Lim SK, Aung T. Efficacy of Phacoemulsification Alone vs Phacoemulsification With Goniosynechialysis in Patients With Primary Angle-Closure Disease: A Randomized Clinical Trial. JAMA Ophthalmol. 2019 Oct 1;137(10):1107-1113. doi: 10.1001/jamaophthalmol.2019.2493.</citation>
    <PMID>31294768</PMID>
  </results_reference>
  <results_reference>
    <citation>Barry M, Alahmadi MW, Alahmadi M, AlMuzaini A, AlMohammadi M. The Safety of the Kahook Dual Blade in the Surgical Treatment of Glaucoma. Cureus. 2020 Jan 16;12(1):e6682. doi: 10.7759/cureus.6682.</citation>
    <PMID>31976190</PMID>
  </results_reference>
  <results_reference>
    <citation>Tanito M, Sugihara K, Tsutsui A, Hara K, Manabe K, Matsuoka Y. Midterm Results of Microhook ab Interno Trabeculotomy in Initial 560 Eyes with Glaucoma. J Clin Med. 2021 Feb 17;10(4). pii: 814. doi: 10.3390/jcm10040814.</citation>
    <PMID>33671386</PMID>
  </results_reference>
  <results_reference>
    <citation>Grover DS, Smith O, Fellman RL, Godfrey DG, Gupta A, Montes de Oca I, Feuer WJ. Gonioscopy-assisted Transluminal Trabeculotomy: An Ab Interno Circumferential Trabeculotomy: 24 Months Follow-up. J Glaucoma. 2018 May;27(5):393-401. doi: 10.1097/IJG.0000000000000956.</citation>
    <PMID>29613978</PMID>
  </results_reference>
  <results_reference>
    <citation>Dorairaj S, Tam MD, Balasubramani GK. Two-Year Clinical Outcomes of Combined Phacoemulsification, Goniosynechialysis, and Excisional Goniotomy For Angle-Closure Glaucoma. Asia Pac J Ophthalmol (Phila). 2020 Oct 6;10(2):183-187. doi: 10.1097/APO.0000000000000321.</citation>
    <PMID>33031110</PMID>
  </results_reference>
  <results_reference>
    <citation>Tham CC, Kwong YY, Baig N, Leung DY, Li FC, Lam DS. Phacoemulsification versus trabeculectomy in medically uncontrolled chronic angle-closure glaucoma without cataract. Ophthalmology. 2013 Jan;120(1):62-7. doi: 10.1016/j.ophtha.2012.07.021. Epub 2012 Sep 15.</citation>
    <PMID>22986111</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xiulan Zhang</investigator_full_name>
    <investigator_title>Director of Clinical Research Center</investigator_title>
  </responsible_party>
  <keyword>Glaucoma, Angle-Closure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

